Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

COVID-19 Phobia in Patients With Bronchiectasis During Covid-19 Pandemic

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04487873
Recruitment Status : Recruiting
First Posted : July 27, 2020
Last Update Posted : December 21, 2020
Sponsor:
Information provided by (Responsible Party):
Merve Firat, Hacettepe University

Tracking Information
First Submitted Date July 23, 2020
First Posted Date July 27, 2020
Last Update Posted Date December 21, 2020
Actual Study Start Date July 23, 2020
Actual Primary Completion Date December 18, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: July 24, 2020)
  • COVID-19 Phobia [ Time Frame: 5 minutes ]
    COVID-19 phobia was evaluated with COVID-19 Phobia Scale (C19P-S) and total score ranges from 20-100. Lower scores mean better outcome.
  • Qol [ Time Frame: 10 minutes ]
    Quality of life was evaluated with Nottingham Health Profile
Original Primary Outcome Measures
 (submitted: July 23, 2020)
  • COVID-19 Phobia [ Time Frame: 5 minutes ]
    COVID-19 phobia was evaluated with COVID-19 Phobia Scale (C19P-S)
  • Qol [ Time Frame: 10 minutes ]
    Quality of life was evaluated with Nottingham Health Profile
Change History
Current Secondary Outcome Measures
 (submitted: July 23, 2020)
  • Health anxiety [ Time Frame: 10 minutes ]
    Health anxiety was evaluated with Health Anxiety Inventory
  • Physical activity [ Time Frame: 5 minutes ]
    Physical activity level was evaluated with International Physical Activity Questionnaire - Short Form (IPAQ-SF)
  • Quality of sleep [ Time Frame: 10 minutes ]
    Quality of sleep was evaluated with Pittsburgh Sleep Quality Index
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title COVID-19 Phobia in Patients With Bronchiectasis During Covid-19 Pandemic
Official Title COVID-19 Phobia and Quality of Life in Patients With Bronchiectasis During Covid-19 Pandemic
Brief Summary In the literature, there are no studies evaluating COVID-19 phobia, quality of life, health anxiety, physical activity level and quality of sleep in patients with bronchiectasis during COVID-19 pandemic. The investigators will evaluate these parameters in patients with bronchiectasis and compare the findings of healthy individuals during COVID-19 pandemic
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Case-Control
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Patients and healthy individuals between 18-60 years old, who are diagnosed with non-cystic fibrosis bronchiectasis, and whose local language is Turkish will be included in the study.
Condition
  • Covid19
  • Bronchiectasis
Intervention Not Provided
Study Groups/Cohorts
  • Bronchiectasis
    Having been diagnosed with non-cystic fibrosis bronchiectasis
  • Healthy individuals
    Healthy individuals without chronic disease
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: July 23, 2020)
28
Original Estimated Enrollment Same as current
Estimated Study Completion Date December 31, 2020
Actual Primary Completion Date December 18, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Having been diagnosed with non-cystic fibrosis bronchiectasis
  • No acute bronchiectasis exacerbation or infection in the past 2 weeks
  • Volunteering to participate in the research

Exclusion Criteria:

  • Having a cognitive problem
  • Not being literate
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 60 Years   (Adult)
Accepts Healthy Volunteers Yes
Contacts
Contact: Merve Firat, MSc +903123051576 mervefirat@hacettepe.edu.tr
Listed Location Countries Turkey
Removed Location Countries  
 
Administrative Information
NCT Number NCT04487873
Other Study ID Numbers GO 20/602
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement Not Provided
Responsible Party Merve Firat, Hacettepe University
Study Sponsor Hacettepe University
Collaborators Not Provided
Investigators
Principal Investigator: Merve Firat, MSc Hacettepe University
Study Director: Naciye Vardar-Yagli, PhD Hacettepe University
Study Chair: Deniz İnal-İnce, Professor Hacettepe University
Study Chair: Melda Saglam, PhD Hacettepe University
Study Chair: Ebru Calik-Kütükcü, PhD Hacettepe University
Study Chair: Aslıhan Cakmak, MSc Hacettepe University
PRS Account Hacettepe University
Verification Date December 2020